Education
About Us
Working with TipRanks
Follow Us
Biodexa Pharmaceuticals (BDRX)
NASDAQ:BDRX
BDRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.00 - $112.96
Previous CloseN/A
Volume6.04K
Average Volume (3M)31.07K
Market Cap
$377.75K
Enterprise Value$1.53M
Total Cash (Recent Filing)$1.67M
Total Debt (Recent Filing)$727.00K
Price to Earnings (P/E)―
Beta1.47
Next Earnings
Sep 11, 2025EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding619,523
10 Day Avg. Volume26,903
30 Day Avg. Volume31,075
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap4.05
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.47
Enterprise Value/Ebitda-0.19
Forecast
1Y Price Target
$18.00Price Target Upside238.35% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
Biodexa Pharmaceuticals News
BDRX FAQ
What was Biodexa Pharmaceuticals’s price range in the past 12 months?
Biodexa Pharmaceuticals lowest stock price was $5.00 and its highest was $112.96 in the past 12 months.
What is Biodexa Pharmaceuticals’s market cap?
Biodexa Pharmaceuticals’s market cap is $377.75K.
When is Biodexa Pharmaceuticals’s upcoming earnings report date?
Biodexa Pharmaceuticals’s upcoming earnings report date is Sep 11, 2025 which is tomorrow.
How were Biodexa Pharmaceuticals’s earnings last quarter?
Biodexa Pharmaceuticals released its earnings results on Apr 11, 2025. The company reported -$0.007 earnings per share for the quarter, missing the consensus estimate of -$0.006 by -$0.001.
Is Biodexa Pharmaceuticals overvalued?
According to Wall Street analysts Biodexa Pharmaceuticals’s price is currently Undervalued.
Does Biodexa Pharmaceuticals pay dividends?
Biodexa Pharmaceuticals does not currently pay dividends.
What is Biodexa Pharmaceuticals’s EPS estimate?
Biodexa Pharmaceuticals’s EPS estimate is >-0.01.
How many shares outstanding does Biodexa Pharmaceuticals have?
Biodexa Pharmaceuticals has 619,523 shares outstanding.
What happened to Biodexa Pharmaceuticals’s price movement after its last earnings report?
Biodexa Pharmaceuticals reported an EPS of -$0.007 in its last earnings report, missing expectations of -$0.006. Following the earnings report the stock price went up 12.739%.
Which hedge fund is a major shareholder of Biodexa Pharmaceuticals?
Currently, no hedge funds are holding shares in BDRX
Company Description
Biodexa Pharmaceuticals
Biodexa Pharmaceuticals (BDRX) is a biotechnology company focused on the development and commercialization of innovative therapeutic solutions. Operating primarily in the pharmaceutical sector, the company specializes in the research and development of drug delivery systems and proprietary drug formulations designed to enhance patient outcomes. Its core products include advanced pharmaceutical compounds and delivery technologies that address unmet medical needs in various therapeutic areas.
Technical Analysis
Kazia Therapeutics
―
Oragenics
―
Xenetic Biosciences
―
NLS Pharmaceutics
―
Pasithea Therapeutics Corp
―
Ownership Overview
1.87%
Insiders
<0.01% Mutual Funds
<0.01% Other Institutional Investors
98.13% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---